查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1388103

掌腱膜攣縮症市場、份額、規模、趨勢、行業分析報告：按類型、按疾病類型、按最終用途、按地區、按細分市場、預測，2023-2032年

Dupuytren Disease Market Share, Size, Trends, Industry Analysis Report, By Type ; By Disease Type ; By End-use ; By Region, And Segment Forecasts, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris 市場研究的最新研究，掌腱膜攣縮症的全球市場預計到 2032 年將達到 65.2 億美元。 該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

掌腱膜攣縮症是一種使人衰弱的疾病，涉及手掌組織異常增厚和縮短，導致手指畸形。 預計的市場擴張表明，有效解決和治療這種疾病的重要性正在被認識。 隨著掌腱膜攣縮症的盛行率持續增加，對有效緩解症狀並改善患者整體生活品質的治療的需求不斷增長。 這種市場擴張反映了對改進治療方案的迫切需要，以應對不斷增長的患者數量並改善患者的福祉。

最近，一項研究表明阿達木單抗是一種有前途且具有成本效益的治療選擇，尤其是在早期階段。 這些研究結果表明，阿達木單抗可以有效控制疾病狀態，同時物有所值。 醫療保健專業人員和患者對該疾病的認識和了解不斷增加，以及醫學研究和診斷的進步，正在推動掌腱膜攣縮症治療選擇市場的擴大。

檢測率的提高和及時幹預增加了對有效治療的需求。 為了解決這個問題，遠籐製藥發起了一項 "觀看教育展開" 活動，以真實患者為主角，旨在提高對該疾病的認識。 該計劃的主要目的是向公眾和醫療保健界宣傳可用的治療方案。 這項活動預計將提高人們對掌腱膜攣縮症的認識，從而實現更早診斷和更好的治療。

此外，醫療技術和治療方法的重大進步，特別是注射膠原蛋白□和微創手術技術的發展，正在推動市場發展。 Xiaflex 是一種經批准的治療方法，它是一種可注射膠原蛋白□，在多個國家用於治療掌腱膜攣縮症。 與傳統外科手術相比，這種方法提供了一種侵入性較小的選擇，從而改善了患者的治療效果並縮短了恢復時間。 醫療技術和治療的進步是整個市場擴張的主要動力。

掌腱膜攣縮症市場報告亮點

II 類比比最大。

開發更有效的治療方案使治療領域獲得最大的市場份額

歐洲透過改善醫療基礎設施和加強產學合作獲得最大的市場份額

主要參與者包括拜耳、諾華、輝瑞、南通清華製藥、Actisa 製藥和遠籐國際。

目錄

第 1 章簡介

第 2 章執行摘要

第 3 章研究方法

第 4 章全球掌腱膜攣縮症市場洞察

  • 掌腱膜攣縮症市場 - 最終用途概況
  • 掌腱膜攣縮症市場動態
    • 推動因素和機會
      • 世界各地的人口老化正在加劇
      • 研究活動更加普遍
    • 抑制因素和挑戰
      • 識別和診斷有限
  • PESTEL 分析
  • 掌腱膜攣縮症市場最終用途趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第 5 章全球掌腱膜攣縮症市場，依類型

  • 主要發現
  • 簡介
  • 診斷
  • 身體檢查
  • X射線
  • 治療
  • 手術
  • 放射治療
  • 針腱膜切開術
  • 類固醇注射
  • 酵素注射液
  • 處理中
  • 職能治療
  • 其他

第 6 章全球掌腱膜攣縮症市場，依疾病類型

  • 主要發現
  • 簡介
  • I 型
  • II 型
  • III 型

第 7 章全球掌腱膜攣縮症市場，依最終用途劃分

  • 主要發現
  • 簡介
  • 醫院
  • 診所
  • 學術/研究機構
  • 其他

第 8 章全球掌腱膜攣縮症市場，按地區

  • 主要發現
  • 簡介
    • 掌腱膜攣縮症市場評估，按地區，2019-2032 年
  • 掌腱膜攣縮症市場 - 北美
    • 北美：掌腱膜攣縮症市場，按類型，2019-2032 年
    • 北美：掌腱膜攣縮症市場，依最終用途劃分，2019-2032 年
    • 北美：掌腱膜攣縮症市場，依疾病類型劃分，2019-2032 年
    • 掌腱膜攣縮症市場 - 美國
    • 掌腱膜攣縮症市場 - 加拿大
  • 掌腱膜攣縮症市場 - 歐洲
    • 歐洲：掌腱膜攣縮症市場，按類型，2019-2032 年
    • 歐洲：掌腱膜攣縮症市場，依最終用途分類，2019-2032 年
    • 歐洲：掌腱膜攣縮症市場，依疾病類型劃分，2019-2032 年
    • 掌腱膜攣縮症市場 - 英國
    • 掌腱膜攣縮症市場 - 法國
    • 掌腱膜攣縮症市場 - 德國
    • 掌腱膜攣縮症市場 - 義大利
    • 掌腱膜攣縮症市場 - 西班牙
    • 掌腱膜攣縮症市場 - 荷蘭
    • 掌腱膜攣縮症市場 - 俄羅斯
  • 掌腱膜攣縮症市場 - 亞太地區
    • 亞太地區：掌腱膜攣縮症市場，按類型，2019-2032 年
    • 亞太地區：掌腱膜攣縮症市場，依最終用途劃分，2019-2032 年
    • 亞太地區：掌腱膜攣縮症市場，依疾病類型劃分，2019-2032 年
    • 掌腱膜攣縮症市場 - 中國
    • 掌腱膜攣縮症市場 - 印度
    • 掌腱膜攣縮症市場 - 馬來西亞
    • 掌腱膜攣縮症市場 - 日本
    • 掌腱膜攣縮症市場 - 印度尼西亞
    • 掌腱膜攣縮症市場 - 韓國
  • 掌腱膜攣縮症市場 - 中東和非洲
    • 中東和非洲：掌腱膜攣縮症市場，按類型，2019-2032 年
    • 中東和非洲：掌腱膜攣縮症市場，依最終用途分類，2019-2032 年
    • 中東和非洲：掌腱膜攣縮症市場，依疾病類型劃分，2019-2032 年
    • 掌腱膜攣縮症市場 - 沙烏地阿拉伯
    • 掌腱膜攣縮症市場 - 阿聯酋
    • 掌腱膜攣縮症市場 - 以色列
    • 掌腱膜攣縮症市場 - 南非
  • 掌腱膜攣縮症市場 - 拉丁美洲
    • 拉丁美洲：掌腱膜攣縮症市場，按類型，2019-2032 年
    • 拉丁美洲：掌腱膜攣縮症市場，依最終用途劃分，2019-2032 年
    • 拉丁美洲：掌腱膜攣縮症市場，依疾病類型劃分，2019-2032 年
    • 掌腱膜攣縮症市場 - 墨西哥
    • 掌腱膜攣縮症市場 - 巴西
    • 掌腱膜攣縮症市場 - 阿根廷

第 9 章競爭態勢

  • 擴張與收購分析
    • 擴大
    • 收購
  • 夥伴關係/協作/協議/揭露

第 10 章公司簡介

  • Actiza Pharmaceutical
  • AstraZeneca
  • Bayer
  • Bristol-Meyers
  • Endo International
  • Fresenius Kabi
  • GSK
  • Hikma Pharmaceuticals
  • LEO Pharma
  • Nantong Jinghua Pharmaceutical
  • Novartis
  • Pfizer
  • Spear Pharmaceuticals
Product Code: PM3797

The global Dupuytren disease market size is expected to reach USD 6.52 billion by 2032, according to a new study by Polaris market research. The report "Dupuytren Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Diagnosis, Treatment); By Disease Type (Type I, Type II, Type III); By End-use (Hospitals, Clinics, Academic & Research Institute, Others); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Dupuytren's disease is a debilitating condition that involves the abnormal thickening & shortening of tissue in the palm, resulting in finger deformities. The projected expansion of the market indicates a growing acknowledgment of the significance of effectively addressing and treating this condition. As the prevalence of Dupuytren's disease continues to increase, there is a rising demand for treatments that can effectively alleviate symptoms and improve the overall quality of life for affected individuals. This market expansion reflects the urgent need for improved therapeutic options to cater to the growing number of patients and enhance their well-being.

Recently, a study has highlighted adalimumab as a promising and cost-effective treatment option, especially in the early stages of the disease. These research findings indicate that adalimumab effectively manages the condition while providing good value for the investment. Growing awareness & knowledge about the disease among healthcare professionals & patients, coupled with advancements in medical research and diagnostics, are driving the expansion of the market for Dupuytren's disease treatment options.

Demand for effective treatments has risen due to improved detection rates and timely intervention. To address this, Endo Pharmaceuticals has launched the "Watching Education Unfold" campaign, which showcases real patients and seeks to raise awareness about the disease. The main objective of this initiative is to educate the public & healthcare community about the treatment options available. As a result of this campaign, it is anticipated that awareness about Dupuytren's contracture will increase, leading to earlier diagnosis and better management of the condition.

Furthermore, the market has been propelled by notable progress in medical technology and therapeutic methods, particularly the development of injectable collagenase and minimally invasive surgical techniques. One such approved treatment is Xiaflex, which employs injectable collagenase for Dupuytren's contracture in several countries. This approach provides a less invasive option compared to traditional surgical procedures, resulting in enhanced patient outcomes and faster recovery periods. These advancements in medical technology and therapeutics have emerged as major driving forces behind the overall expansion of the market.

Dupuytren Disease Market Report Highlights

Type II segment held the largest share, owing to its high prevalence, and more innovative treatment options

Treatment segment garnered the largest share, due to development of better treatment options with higher efficacy

Europe held the largest share, due to better healthcare infrastructure, strong indudtry-academia collaboration

Key players include Bayer, Novartis, Pfizer, Nantong Jinghua Pharmaceutical, Actiza Pharmaceutical, Endo International

Polaris market research has segmented the Dupuytren disease market report based on disease type, type, end use, and region:

Dupuytren Disease, Disease Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Type I
  • Type II
  • Type III

Dupuytren Disease, Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Diagnosis
  • Physical Examination
  • X-ray
  • Treatment
  • Surgery
  • Radiation Therapy
  • Needle Aponeurotomy
  • Steroid Shot
  • Enzyme Injection
  • Occupational Therapy
  • Others

Dupuytren Disease, End Use Outlook (Revenue - USD Billion, 2023 - 2032)

  • Hospitals
  • Clinics
  • Academic & Research Institute
  • Others

Dupuytren Disease, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Dupuytren Disease Market Insights

  • 4.1. Dupuytren Disease Market - End Use Snapshot
  • 4.2. Dupuytren Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing aging population worldwide
      • 4.2.1.2. Rising Prevalence of Research Activities
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Awareness and Diagnosis
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Dupuytren Disease Market End Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Dupuytren Disease Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Diagnosis
    • 5.3.1. Global Dupuytren Disease Market, by Diagnosis, by Region, 2019-2032 (USD Billion)
  • 5.4. Physical Examination
    • 5.4.1. Global Dupuytren Disease Market, by Physical Examination, by Region, 2019-2032 (USD Billion)
  • 5.5. X-ray
    • 5.5.1. Global Dupuytren Disease Market, by X-ray, by Region, 2019-2032 (USD Billion)
  • 5.6. Treatment
    • 5.6.1. Global Dupuytren Disease Market, by Treatment, by Region, 2019-2032 (USD Billion)
  • 5.7. Surgery
    • 5.7.1. Global Dupuytren Disease Market, by Surgery, by Region, 2019-2032 (USD Billion)
  • 5.8. Radiation Therapy
    • 5.8.1. Global Dupuytren Disease Market, by Radiation Therapy, by Region, 2019-2032 (USD Billion)
  • 5.9. Needle Aponeurotomy
    • 5.9.1. Global Dupuytren Disease Market, by Needle Aponeurotomy, by Region, 2019-2032 (USD Billion)
  • 5.10. Steroid Shot
    • 5.10.1. Global Dupuytren Disease Market, by Steroid Shot, by Region, 2019-2032 (USD Billion)
  • 5.11. Enzyme Injection
    • 5.11.1. Global Dupuytren Disease Market, by Enzyme Injection, by Region, 2019-2032 (USD Billion)
  • 5.12. Treatment
    • 5.12.1. Global Dupuytren Disease Market, by Treatment, by Region, 2019-2032 (USD Billion)
  • 5.13. Occupational Therapy
    • 5.13.1. Global Dupuytren Disease Market, by Occupational Therapy, by Region, 2019-2032 (USD Billion)
  • 5.14. Others
    • 5.14.1. Global Dupuytren Disease Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Dupuytren Disease Market, by Disease Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 6.3. Type I
    • 6.3.1. Global Dupuytren Disease Market, by Type I, by Region, 2019-2032 (USD Billion)
  • 6.4. Type II
    • 6.4.1. Global Dupuytren Disease Market, by Type II, by Region, 2019-2032 (USD Billion)
  • 6.5. Type III
    • 6.5.1. Global Dupuytren Disease Market, by Type III, by Region, 2019-2032 (USD Billion)

7. Global Dupuytren Disease Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Dupuytren Disease Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.4. Clinics
    • 7.4.1. Global Dupuytren Disease Market, by Clinics, By Region, 2019-2032 (USD Billion)
  • 7.5. Academic & Research Institute
    • 7.5.1. Global Dupuytren Disease Market, by Academic & Research Institute, By Region, 2019-2032 (USD Billion)
  • 7.6. Others
    • 7.6.1. Global Dupuytren Disease Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Dupuytren Disease Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Dupuytren Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Dupuytren Disease Market - North America
    • 8.3.1. North America: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.3.4. Dupuytren Disease Market - U.S.
      • 8.3.4.1. U.S.: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.3.5. Dupuytren Disease Market - Canada
      • 8.3.5.1. Canada: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 8.4. Dupuytren Disease Market - Europe
    • 8.4.1. Europe: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.4. Dupuytren Disease Market - UK
      • 8.4.4.1. UK: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.5. Dupuytren Disease Market - France
      • 8.4.5.1. France: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.6. Dupuytren Disease Market - Germany
      • 8.4.6.1. Germany: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.7. Dupuytren Disease Market - Italy
      • 8.4.7.1. Italy: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.8. Dupuytren Disease Market - Spain
      • 8.4.8.1. Spain: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.9. Dupuytren Disease Market - Netherlands
      • 8.4.9.1. Netherlands: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.10. Dupuytren Disease Market - Russia
      • 8.4.10.1. Russia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 8.5. Dupuytren Disease Market - Asia Pacific
    • 8.5.1. Asia Pacific: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.4. Dupuytren Disease Market - China
      • 8.5.4.1. China: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.5. Dupuytren Disease Market - India
      • 8.5.5.1. India: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.6. Dupuytren Disease Market - Malaysia
      • 8.5.6.1. Malaysia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.7. Dupuytren Disease Market - Japan
      • 8.5.7.1. Japan: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.8. Dupuytren Disease Market - Indonesia
      • 8.5.8.1. Indonesia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.9. Dupuytren Disease Market - South Korea
      • 8.5.9.1. South Korea: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 8.6. Dupuytren Disease Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.4. Dupuytren Disease Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.5. Dupuytren Disease Market - UAE
      • 8.6.5.1. UAE: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.6. Dupuytren Disease Market - Israel
      • 8.6.6.1. Israel: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.7. Dupuytren Disease Market - South Africa
      • 8.6.7.1. South Africa: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • 8.7. Dupuytren Disease Market - Latin America
    • 8.7.1. Latin America: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.4. Dupuytren Disease Market - Mexico
      • 8.7.4.1. Mexico: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.5. Dupuytren Disease Market - Brazil
      • 8.7.5.1. Brazil: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.6. Dupuytren Disease Market - Argentina
      • 8.7.6.1. Argentina: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Actiza Pharmaceutical
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2.AstraZeneca
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bayer
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bristol-Meyers
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Endo International
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Fresenius Kabi
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GSK
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Hikma Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. LEO Pharma
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Nantong Jinghua Pharmaceutical
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Novartis
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Pfizer
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Spear Pharmaceuticals
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development

List of Tables

  • Table 1 Global Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 3 Global Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 4 Dupuytren Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 7 North America: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion
  • Table 14 Europe: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 17 UK: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 19 UK: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 20 France: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 22 France: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 41 China: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 43 China: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 44 India: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 46 India: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Dupuytren Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Dupuytren Disease Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Dupuytren Disease Market, by End Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Dupuytren Disease Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Disease Type
  • Figure 7. Global Dupuytren Disease Market, by Disease Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Dupuytren Disease Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Dupuytren Disease Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 12. Dupuytren Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Dupuytren Disease Market